Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program February 1, 2021
Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09 November 2, 2020
Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering October 28, 2020
Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09 October 28, 2020
